STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept

Patrick Soon-Shiong has faced criticism regarding his claims about cancer drug efficacy, particularly in pancreatic cancer treatment. Critics, including the author of the Biotech Scorecard, argue that Soon-Shiong's pronouncements often lack substantial clinical evidence and are financially motivated, leading to "FDA wrist-slapping." The author notes a significant discrepancy between Soon-Shiong's stated capabilities of his cancer drugs and their actual performance in real-world clinical trials. Soon-Shiong's personal history includes treating diabetic patients with pancreas transplants and performing surgery on pancreatic cancer patients, which he states inspired his "Bioshield" mission to transform pancreatic cancer treatment through novel immunotherapies. However, the author contends that the "Bioshield" mission, like other initiatives, has not consistently delivered on its ambitious promises. The article suggests that Soon-Shiong's public statements about his cancer therapies are often "fluff" rather than grounded in verifiable scientific progress. This critique highlights a recurring pattern of overpromising and underdelivering associated with Soon-Shiong's ventures in the biotechnology and cancer research fields. The author acknowledges the laudable goal of eradicating cancer but questions the methods and transparency of Soon-Shiong's approach.